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Abstract  Despite  high  prevalence  of  iron  deﬁciency  anemia  (IDA)  in  patients  with  acute  or
chronic gastrointestinal  bleeding  (GIB),  IDA  and  iron  deﬁciency  (ID)  are  frequently  untreated.
Reasons  may  be  misconceptions  about  the  impact  and  diagnosis  of  IDA  and  the  efﬁcacy  of  new
treatments.  Addressing  these  misconceptions,  this  article  summarizes  current  evidence  for  bet-bleeding;
Diagnosis;
ter understanding  and  management  of  GIB-associated  IDA.  Despite  only  few  controlled  studies
evaluated the  efﬁcacy  of  iron  treatment  in  patients  with  GIB,  there  is  consistent  evidenceTreatments suggesting  that:  (a)  IDA  should  be  diligently  investigated,  (b)  effective  treatment  of  ID/IDA Please cite this article as: Mearin F, Lanas Á, Bujanda L, Canelles P, Cotter J, Hervás A, et al. Preguntas y errores en el diagnóstico y
manejo de la anemia en pacientes con hemorragia digestiva. Gastroenterol Hepatol. 2018;41:63--76.
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improves  outcomes  such  as  health-related  quality  of  life  and  can  avoid  severe  cardiovascular
consequences,  and  (c)  intravenous  iron  should  be  considered  as  well-tolerated  treatment  in  this
setting. Overall,  the  misconceptions  and  practices  outlined  in  this  article  should  be  replaced
with strategies  that  are  more  in  line  with  current  guidelines  and  best  practice  in  GIB  and  other
underlying conditions  of  ID/IDA.
©  2017  The  Author(s).  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an  open  access  article  under
the CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Preguntas  y  errores  en  el  diagnóstico  y  manejo  de  la  anemia  en  pacientes
con  hemorragia  digestiva
Resumen  A  pesar  de  la  alta  prevalencia  de  anemia  por  déﬁcit  de  hierro  (ADH)  en  pacientes  con
hemorragia  digestiva  (HD)  aguda  o  crónica,  la  ADH  y  el  déﬁcit  de  hierro  (DH)  son  frecuentemente
infratratados.  Diversos  conceptos  erróneos  sobre  el  impacto,  el  diagnóstico  y  la  eﬁcacia  de
los nuevos  tratamientos  de  la  ADH  probablemente  lo  justiﬁcan.  Para  abordar  estos  errores
conceptuales,  este  artículo  resume  la  evidencia  actual  para  una  mejor  comprensión  y  manejo
de la  ADH.  A  pesar  de  que  existen  pocos  estudios  controlados  que  hayan  evaluado  la  eﬁcacia
del tratamiento  con  hierro  en  pacientes  con  HD,  hay  evidencia  que  sugiere  que:  (a)  la  ADH  debe
ser investigada  diligentemente;  (b)  el  tratamiento  eﬁcaz  del  DH/ADH  mejora  la  calidad  de  vida
relacionada  con  la  salud  y  puede  evitar  relevantes  complicaciones  cardiovasculares,  y  (c)  el
hierro intravenoso  debe  ser  considerado  como  un  tratamiento  bien  tolerado  en  este  contexto.
En general,  los  conceptos  erróneos  y  las  prácticas  inadecuadas  descritas  en  este  artículo  deben
ser reemplazados  por  estrategias  que  estén  más  en  línea  con  las  directrices  actuales  y  buenas
prácticas  clínicas  en  HD  y  otras  condiciones  causantes  del  DH/ADH.
© 2017  El  Autor(s).  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un  art´ıculo  Open  Access  bajo
la licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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astrointestinal  bleeding  (GIB)  is  a  common  complication
f  many  gastrointestinal  conditions.1--7 One  of  the  most
omprehensive  U.S.  data  for  peptic  ulcer  disease  and  GIB,
ollected  from  2001  to  2009,  indicated  approximately  66
ases  per  100,000  population  for  upper  GIB  and  223/100,000
or  any  GIB,8 with  substantial  increases  to  hospitalization
osts  and  length  of  stay.9 While  hospitalizations  due  to  upper
IB  (particularly  due  to  peptic  ulcer  bleeding  and  perfora-
ion)  decreased  over  the  recent  years,  varices  and  lower  GIB
particularly  colonic  diverticular  and  angiodysplasia  bleed-
ng)  remained  common  or  even  increasing  conditions.10,11
here  have  been  few  advances  in  GIB  management,  yet  costs
re  likely  to  have  increased.
GIB  is  the  most  frequent  reason  for  iron  deﬁciency  (ID)
nd  iron  deﬁciency  anemia  (IDA)  in  adult  men  and  post-
enopausal  women.12,13 In  turn,  IDA  is  a  common  cause
f  referral  to  gastroenterologists  and  internists,12 can  lead
o  hospitalization,  contribute  to  fatigue,  affect  health-
elated  quality  of  life  (QoL),14--16 and  can  be  associated
ith  increased  mortality  in  certain  populations.17--19 The
ole  of  IDA  as  a  common  co-morbidity  across  a  wide  range
f  gastrointestinal  and  liver  disorders  has  been  reviewed
s
n
aecently.20 Accordingly,  early  detection  and  cost-effective
anagement  of  anemia  and  ID  would  be  in  the  interest  of
oth  patients  and  health  care  systems.
While  the  occurrence  of  IDA  in  inﬂammatory  bowel  dis-
ase  (IBD)  is  well  reported,21--23 prevalence  data  on  IDA
ssociated  with  GIB  are  scarce.  Part  of  the  challenge  in
ecording  and  characterizing  GIB-associated  IDA  is  the  het-
rogeneity  of  underlying  gastrointestinal  conditions.5,12,14
DA  is  typically  attributed  to  occult  bleeding  from  either  the
pper  or  lower  GI  tract.7 Furthermore,  age  and  age-related
alnutrition  or  medications,  such  as  acetylsalicylic  acid
ASA)  or  nonsteroidal  anti-inﬂammatory  drugs  (NSAIDs),  and
ntithrombotics/anticoagulants,  can  promote  or  aggravate
IB  and  consequently  IDA.24 Other  gastrointestinal-related
auses  of  IDA  include  extensive  bowel  resection,  associated
ietary  restrictions,  malabsorption,  and  Helicobacter  pylori
nfection.25--29 Finally,  IDA  can  be  a  post-hemorrhage  conse-
uence  of  an  insufﬁcient  management  of  major  overt  GIB
vent.
Due  to  the  paucity  of  data  and  guidelines  covering  GIB
cross  different  underlying  gastrointestinal  conditions,
everal  open  questions  and  misconceptions  on  the  diag-
osis  and  management  of  ID  and  IDA  in  patients  with  GIB
rose  over  time  (Table  1).  This  review  aims  to  summarize
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Table  1  Common  misconceptions  and  clariﬁcation  about  iron  deﬁciency  and  iron  deﬁciency  anemia  in  patients  with  gastroin-
testinal bleeding.
1.  Prevalence  and  impact  of  anemia
1a. Anemia  is  generally  mild  in  patients  with  GIB
→ Anemia  is  frequently  moderate  or  severe  in  patients  with  GIB
1b.  The  impact  of  IDA  on  the  quality  of  life  of  GIB  patients  is  very  limited
→ The  impact  of  IDA  on  the  quality  of  life  of  GIB  patients  is  important
2.  Diagnosis
2a.  Doctors  are  sensitive  to  detect  and  treat  anemia  during  hospitalization  and  discharge  of  patients  with  acute
and overt  GIB
→  Doctors  are  usually  not  sensitive  to  detect  and  treat  anemia  during  hospitalization  of  patients  with  GIB
2b.  Ferritin  is  accurate  enough  for  the  diagnosis  and  monitoring  of  ID  in  GIB
→
Ferritin  alone  is  not  accurate  enough  for  the  diagnosis  of  ID  in  GIB  and  for  the  monitoring  after  i.v.  iron  administration
2c.  Anemia  but  not  ID  is  the  only  relevant  laboratory  ﬁnding  in  GIB
→ Iron  deﬁciency  with  or  without  anemia  is  a  relevant  laboratory  ﬁnding  in  GIB
3.  Treatment  goals  and  efﬁcacy
3a. All  patients  with  GIB  and  IDA  are  quite  similar  and,  therefore,  one  treatment  approach  for  IDA  ﬁts  all
→ Patients  with  GIB  and  IDA  are  heterogeneous  and  require  an  individualized  treatment  approach  for  IDA
3b.  When  treating  IDA  with  iron  supplementation  in  patients  undergoing  a  GIB  event,  the  aim  is  just  to  increase
but not  necessarily  normalize  Hb  values
→ When  treating  IDA  with  iron  supplementation  in  GIB,  the  aim  is  to  achieve  normal  Hb  values
3c.  Intravenous  iron  administration  should  be  reserved  for  GIB  patients  with  very  severe  anemia  (e.g.  Hb  <8  g/dL)
→ Intravenous  iron  administration  should  not  be  reserved  only  for  GIB  patients  with  very  severe  anemia
3d.  When  treating  IDA  with  i.v.  iron  administration,  a  dose  of  500  or  up  to  1000  mg  is  enough
→ Total  doses  of  i.v.  iron  administration  should  be  individualized  but  frequently  are  higher  than  1000  mg;  most  available
clinical  data  are  based  on  single  doses  of  up  to  1000  mg  iron
3e.  The  correction  of  IDA  after  i.v.  iron  administration  is  practically  immediate
→ The  correction  of  IDA  after  i.v.  iron  administration  is  rapid  but  takes  some  time  (several  weeks)
3f.  The  efﬁcacy  of  i.v.  iron  for  the  treatment  of  IDA  in  GIB,  in  contrast  with  non-GIB  patients,  has  not  been
demonstrated
→ The  effectiveness  of  i.v.  iron  for  the  treatment  of  IDA  in  patients  with  GIB  is  demonstrated
3g.  Intravenous  iron  treatment  is  unsafe
→ Intravenous  iron  treatment  is  safe
3h.  Red  blood  cell  transfusion  is  indicated  in  hemodynamically  stable  patients  when  Hb  drops  below  8--9  g/dL
→ Blood  transfusion  is  not  indicated  in  hemodynamically  stable  patients  when  Hb  is ≥7--8 g/dL
3i.  After  initiation  of  blood  transfusion,  no  further  i.v.  iron  treatment  is  needed
→ Even  after  blood  transfusion,  i.v.  iron  treatment  is  needed  in  most  cases
3j.  When  oral  iron  is  administered,  higher  doses  than  usual  should  be  prescribed  in  patients  with  GIB
→ When  oral  iron  is  administered,  higher  doses  than  usual  should  not  be  prescribed  in  patients  with  GIB
3k.  The  response  of  IDA  to  oral  iron  supplementation  is  almost  invariably  excellent  in  GIB
→ The  response  of  IDA  to  the  oral  iron  supplementation  is  variable  and  depends  on  factors  such  as  age,  gender,
concomitant  medications  and  comorbidity
3l.  Treatment  with  i.v.  iron  has  no  role  in  the  patients  with  GIB  seen  in  the  emergency  room  for  self-limiting
bleeding who  are  discharged  early,  without  being  admitted  to  hospital
→ Treatment  with  i.v.  iron  may  be  crucial  in  patients  with  IDA  seen  in  the  emergency  room  for  self-limiting
bleeding  who  are  discharged  early,  without  even  being  admitted  to  hospital
4.  Other
4a.  The  role  of  the  gastroenterologist  ends  when  the  GIB  event  is  controlled  (stopping  GIB  is  the  priority,  anemia
is not  relevant)
→  The  role  of  the  gastroenterologist  is  not  only  to  control  the  GIB  event  but  also  to  treat  IDA  and  ID
4b.  Intravenous  iron  formulations  are  expensive  and  not  cost-effective
→ Intravenous  iron  can  be  cost-effective
GIB, gastrointestinal bleeding; Hb, hemoglobin; i.v., intravenous; ID, iron deﬁciency; IDA, iron deﬁciency anemia.
6c
u
o
a
c
l
a
a
m
P
M
p
W
<
m
<
t
s
r
a
s
c
p
u
a
c
i
p
a
p
o
m
i
e
s
M
a
w
T
A
r
o
o
s
m
m
w
Q
b
f
e
g
o
g
S
c
s
a
c
s
I
d
w
l
D
M
a
d
g
E
G
d
A
h
m
s
s
M
I
t
h
m
c
c
i
f
s
d
r
t
d
w
M
t
gastrointestinal  bleeding6  
urrently  available  and  burgeoning  evidence  for  better
nderstanding  of  GIB-associated  IDA  and  improvement
f  patient  outcomes,  in  order  to  address  this  modiﬁ-
ble  but  often  unconsidered  risk.  The  summaries  and
onclusions  are  a  result  of  expert  discussions  based  on  pub-
ished  literature  and  expert  experience.  They  reﬂect  the
uthors’  collective,  independent  opinion  with  unanimous
greement  on  how  to  address  these  open  questions  and
isconceptions.
revalence and impact of anemia
isconception  1a:  Anemia  is  generally  mild  in
atients with  any  gastrointestinal  bleeding
hile  anemia  in  adults  is  deﬁned  by  hemoglobin  (Hb)
13  g/dL  in  men  or  <12  g/dL  in  women  (moderate  ane-
ia  Hb  <10  g/dL,  severe  anemia  Hb  <8.0  g/dL),  Hb  levels
12  g/dL  in  men  and  <10  g/dL  in  women  should  be  inves-
igated  more  urgently,  since  lower  Hb  levels  suggest  more
erious  disease.12 The  World  Health  Organization’s  most
ecent  Global  Burden  of  Disease  study  showed  a  33%  global
nemia  prevalence  in  2010  with  15%  of  episodes  being  clas-
iﬁed  as  moderately  to  severely  anemic.30
Data  speciﬁc  for  patients  with  either  acute  overt  or
hronic  (non-oncological)  GIB  and  IDA  are  scarce.  Among
atients  who  had  been  admitted  for  non-variceal  acute
pper  GIB  (AUGIB)  to  a  Danish  university  hospital,  50%  had
 Hb  <10  g/dL  at  admission  and  80%  were  still  anemic  at  dis-
harge  (median  Hb  10.6  g/dL).1 A  recent  multicenter  study
n  Spain  (REGIS),31 which  investigated  characteristics  of  379
atients  hospitalized  for  gastrointestinal  diseases,  showed
 60%  anemia  prevalence  at  admission  with  half  of  those
atients  being  severely  anemic  (Hb  <10  g/dL).  Patients  with
ccult  GIB  (chronic  bleeding  of  unknown  origin)  had  a low
ean  Hb  of  8.0  g/dL.  Despite  the  absence  of  similar  studies
n  other  countries,  it  is  very  likely  that  these  results  can  be
xtrapolated  to  other  geographic  areas.
Authors’  conclusion:  Anemia  is  frequently  moderate  or
evere  in  patients  with  GIB.
isconception  1b:  The  impact  of  iron  deﬁciency
nemia on  health-related  quality  of  life  of  patients
ith gastrointestinal  bleeding  is  very  limited
he  impact  of  IDA  on  QoL  is  often  underestimated  or  ignored.
lthough  patients  tend  to  adapt  to  low  Hb  levels,32,33 this  is
ather  an  adaptation  to  a  lower  QoL.
QoL  studies  in  patients  with  speciﬁc  GIB-lesions  and  IDA
r  related  symptoms  are  scarce  and  small.34,35 A  sub-study
f  a  trial  on  iron  treatment  in  patients  with  acute  GIB
howed  that  patients  who  were  non-anemic  after  three
onths  treatment  had  a  higher  overall  health-related  QoL
ean  index  than  anemic  patients.34 Although  this  difference
as  not  statistically  signiﬁcant,  it  is  noteworthy  that  the
oL  mean  index  remained  stable  in  non-anemic  patients
I
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ut  decreased  substantially  in  anemic  patients  over  the
ollowing  three  months,  resulting  in  signiﬁcantly  differ-
nt  proportions  of  patients  who  achieved  normal  age-  and
ender-matched  health-related  QoL.  In  patients  with  IBD
r  other  conditions  associated  with  IDA,  QoL  studies  sug-
est  that  IDA  has  a  substantial  impact  on  QoL.32,33,36--39
tudies  in  iron-treated  patients  with  IBD  showed  signiﬁ-
ant  improvements  of  QoL  compared  to  baseline.38,40 One
tudy  even  correlated  single-unit  increases  in  Hb  levels
nd  improvements  in  quality  of  life  scores  independent  of
hanges  in  disease  activity.  Considering  that  IDA  can  affect
everal  body  systems,33 one  can  expect  a  similar  impact  of
DA  on  QoL  in  patients  with  GIB.  Notably,  even  before  the
ecline  of  Hb  to  anemic  levels,  ID  can  already  affect  QoL  as
ell  as  cognitive  and  behavioral  functioning.41--43
Authors’  conclusion:  The  impact  of  IDA  on  the  quality  of
ife  of  GIB  patients  is  important.
iagnosis
isconception  2a:  Doctors  are  sensitive  to  detect
nd treat  anemia  during  hospitalization  and
ischarge of  patients  with  acute  and  overt
astrointestinal  bleeding
vidence  suggests  just  the  opposite:  among  patients  with
IB  in  the  REGIS  study,  the  prevalence  of  severe  anemia
id  not  change  signiﬁcantly  from  admission  to  discharge.31
nemia  was  frequently  ignored  or  left  untreated  in  patients
ospitalized  for  gastrointestinal  diseases  with  58%  still  ane-
ic  (17%  severely  anemic)  at  discharge.  Similarly,  another
tudy  in  patients  hospitalized  with  non-variceal  AUGIB
howed  that  >80%  were  anemic  at  the  time  of  discharge.1
oreover,  most  patients  with  non-variceal  AUGIB  develop
DA  within  30  days  after  the  episode,44 suggesting  subop-
imal  treatment  of  IDA  for  a  considerable  proportion  of
ospital  admissions.
These  ﬁndings  in  GIB  are  in  line  with  a  recent  study  on  the
anagement  of  IBD-associated  anemia  and  ID  in  9  European
ountries.45 This  study  showed  that  the  diagnostic  tests  and
riteria  used  to  assess  or  conﬁrm  ID/IDA  varied  considerably,
mplying  guidelines  were  not  adhered.  Furthermore,  high
requencies  of  severe  anemia  (15%)  and  absolute  ID  (76%)
uggest  insufﬁcient  monitoring  and  iron  repletion  in  routine
isease  management.  In  contrast  to  the  available  published
ecommendation  preferring  intravenous  (i.v.)  over  oral  iron
reatment,21 only  28%  received  i.v.  iron.
Authors’  conclusion:  Doctors  are  usually  not  sensitive  to
etect  and  treat  anemia  during  hospitalization  of  patients
ith  GIB.
isconception  2b:  Ferritin  is  accurate  enough  for
he diagnosis  and  monitoring  of  iron  deﬁciency  inn  patients  with  AUGIB,  not  only  baseline  levels  of  Hb  and
erritin  but  also  levels  of  Hb  and  transferrin  saturation
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treatment.Anemia:  Misconceptions  in  gastrointestinal  bleeding  
(TSAT)  ﬁve  days  after  GIB  were  predictive  for  the  devel-
opment  of  IDA  30  days  after  the  GIB  episode  (patients
did  not  receive  i.v.  iron  but  transfusions  when  being
hemodynamically  instable).44 Also,  patients  with  acute  GIB
may  have  an  unknown  or  untreated  chronic  inﬂamma-
tion  or  comorbidities  that  can  result  in  falsely  normal
or  increased  ferritin  levels  because  ferritin  is  an  acute
phase  reactant.46 Accordingly,  diagnostic  criteria  for  ID
should  be  adapted  to  the  potential  or  actually  conﬁrmed
presence  of  inﬂammation  (e.g.  via  elevated  levels  of  C-
reactive  protein,  endoscopic  ﬁndings,  diarrhea).  TSAT  and
red  blood  cell  indices  such  as  the  hemoglobin  content
of  reticulocytes  or  the  percentage  of  hypochromic  cells
are  less  prone  to  such  inﬂuences.  Accordingly,  half  of
22  professional-association  guidelines  on  the  diagnosis  and
treatment  of  ID  in  different  indications  propose  TSAT  as
an  alternative  or  complementary  diagnostic  test  besides
serum  ferritin.47 The  British  Society  of  Gastroenterology
guideline  for  the  management  of  IDA  in  digestive  diseases
proposes  ID  as  serum  ferritin  below  15--50  g/L,  depending
on  inﬂammatory  status.12 In  IBD-associated  anemia,  consen-
sus  recommendations  suggest  that  the  lower  limits  of  serum
ferritin  and  TSAT  in  patients  with  evidence  of  inﬂammation
should  be  100  g/L  and  16--20%,  respectively.21,48,49 With-
out  evidence  of  inﬂammation  or  liver  damage,  a  serum
ferritin  <30  g/L  is  indicative  of  ID.50 In  addition  to  Hb,
iron  status  and  markers  of  inﬂammation  or  liver  damage
(C-reactive  protein,  alanine  aminotransferase),  a  full  evalu-
ation  should  also  include  vitamin  B12  and  folic  acid  levels  as
recommended  by  the  European  guidelines  for  patients  with
IBD.48,49
Overall,  iron  status  should  be  monitored  to  minimize
the  risk  of  newly  developed  or  recurrent  ID  and  IDA  in
the  context  of  the  patient’s  condition  and  management
of  GIB.  For  monitoring,  the  British  Society  of  Gastroenter-
ology  proposes  that  Hb  levels  and  red  blood  cell  indices  are
assessed  at  3-monthly  intervals  for  one  year,  then  after  a
further  year,  and  immediately  in  case  symptoms  of  ID/IDA
reoccur.12
In  the  primary  care  setting,  where  nutritional  deﬁcien-
cies,  cancer/chemotherapy,  or  chronic  renal  failure  can  be
easily  ruled  out,  ferritin  values,  combined  with  standard  lab-
oratory  tests  and  a  complete  blood  count,  can  be  considered
accurate  enough  to  diagnose  ID  or  IDA.51
Authors’  conclusion:  Assessment  of  ferritin  levels  as  sole
iron  status  parameter  is  not  accurate  enough  for  the  diagno-
sis  of  ID  in  GIB  and  for  the  monitoring  of  iron  status  before
or  after  i.v.  iron  administration.
Misconception  2c:  Anemia  but  not  iron  deﬁciency
is the  only  relevant  laboratory  ﬁnding  in
gastrointestinal  bleedingNotably,  any  chronic  illness  can  disrupt  iron  homeostasis
and  ultimately  reduce  the  availability  of  iron  for  effective
erythropoiesis  and  hemoglobin  production,50 and  untreated
ID  will  likely  progress  to  IDA.  Therefore,  regular  assess-
h
a67
ent  of  iron  status  (ferritin  and  TSAT)  is  supported,  with
dequate  workup  and  consideration  to  the  clinical  conse-
uences  of  disturbances  in  iron  status.12 The  relevance  of
D  beyond  just  being  a laboratory  measure  is  indicated  by
tudies  in  different  populations,  showing  that  ID  can  affect
oL  and  cognitive  functioning  even  before  the  onset  of
nemia.  Furthermore,  iron  repletion  improved  functional
s  well  as  QoL  outcomes  in  ID  patients  with  and  with-
ut  anemia.41--43,52,53 A  recently  presented  study  among
atients  with  IBD  in  a  Spanish  outpatient  clinic  showed
hat  37%  were  iron  deﬁcient  but  non-anemic,  and  these
atients  had  signiﬁcantly  lower  QoL  (CCVEII-9)  and  fatigue
FACIT-F)  scores  than  patients  with  normal  iron  and  Hb
tatus.54
Authors’  conclusion:  Iron  deﬁciency  with  or  without  ane-
ia  is  a  relevant  laboratory  ﬁnding  in  GIB.
reatment goals and efﬁcacy
isconception  3a:  All  patients  with  gastrointestinal
leeding and  iron  deﬁciency  anemia  are  quite
imilar and,  therefore,  one  treatment  approach  for
ron deﬁciency  anemia  ﬁts  all
uidelines  for  the  treatment  of  AUGIB  hardly  address  IDA,
nd  in  case  they  do,  red  blood  cell  (RBC)  transfusion  is  the
nly  suggested  treatment  for  patients  with  Hb  levels  below
--8  g/dL.55 However,  it  is  essential  to  consider  also  other
atient  characteristics  that  can  differently  inﬂuence  the
tiology  of  GIB  and  IDA,  e.g.  advanced  age,  comorbidities
especially  heart  failure  and  chronic  obstructive  pulmonary
isease)  or  medications  such  as  anticoagulants  (given  to
pproximately  30%  of  patients  with  treated  IDA),56,57 ASA,
SAIDs  and  proton  pump  inhibitors  (PPIs).58,59 Although  anti-
oagulants  are  transiently  suspended  during  active  bleeding,
hey  are  reintroduced  shortly  after  a  bleeding  period,  par-
icularly  in  patients  with  heart  failure,  atrial  ﬁbrillation
r  cardiac  valve  diseases,  increasing  the  risk  of  recurrent
leeding  and  IDA.  Furthermore,  conditions  associated  with
cute  or  chronic  inﬂammation  and  co-medication  with  PPIs
hat  increase  the  gastric  pH  can  affect  the  efﬁcacy  of
ral  iron.50,60 Intravenous  iron  therapy  is  less  dependent
n  such  patient  characteristics  and  has  a  substantial  dif-
erent  gastrointestinal  side  effect  proﬁles  than  oral  iron,21
owever,  approved  dose  limits  differ  between  different  i.v.
ron  preparations  according  to  their  stability.61 With  respect
o  oral  iron,  one  should  consider  the  stool  coloring  effect
hat  may  either  frighten  patients  suspecting  to  have  a  new
leeding  event  (even  if  they  have  been  informed  about  that
ffect  by  their  physician)  or  conversely,  miss  this  typical
ign  of  bleeding  since  they  judge  it  as  side  effect  of  theAuthors’  conclusion:  Patients  with  GIB  and  IDA  are
eterogeneous  and  require  an  individualized  treatment
pproach  for  IDA.
6 F.  Mearin  et  al.
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Table  2  Estimated  total  iron  deﬁcit  (mg  elemental  iron)
based on  hemoglobin  and  body  weight.77
Patient  body
weight  35  to
<70  kg
Patient  body
weight
≥70  kg
Hemoglobin  <10  g/dL  1500  mg  2000  mg
Hemoglobin  10--14  g/dL  1000  mg  1500  mg
Hemoglobin  >14  g/dL  500  mga 500  mga
a In case of conﬁrmed diagnosis of iron deﬁciency.
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isconception  3b:  When  treating  iron  deﬁciency
nemia with  iron  supplementation  in  patients
ndergoing  a  gastrointestinal  bleeding  event,  the
im is  just  to  increase  but  not  necessarily
ormalize hemoglobin  values
he  overall  aims  of  treating  IDA  are  to  normalize  Hb  lev-
ls,  and  to  replenish  iron  stores.12 A  study  investigating
atients  hospitalized  for  new  or  worsening  heart  failure
howed  a  sharp  reduction  in  mortality  among  patients
ith  Hb  levels  that  are  closer  to  normal  (13  g/dL)  at
ospital  admission.62 In  two  separate  studies  following-up
atients  with  chronic  heart  failure  (CHF),  multivariate  anal-
sis  showed  that  anemia  (Hb  <12  g/dL)  is  an  independent
isk  factor  for  mortality  and  heart  failure-related  read-
ission,  with  rates  of  approx.  30%  in  anemic  and  15%
n  non-anemic  patients.  The  beneﬁt  of  even  incremen-
al  increases  of  Hb  levels  has  been  shown  in  different
atient  populations  where  Hb  increase  and  not  necessarily
b  normalization  correlated  with  improvements  of  QoL.38,63
mong  patients  with  acute  GIB  who  had  received  a  three-
onth  anemia  treatment,  approximately  60%  of  patients
ith  resolved  anemia  but  only  about  30%  of  patients  with
nresolved  anemia  had  normal  QoL  scores  three  months’
ost-treatment.34
After  hospital  discharge,  follow-up  of  IDA  patients  should
ddress  the  goal  to  raise  and  maintain  normal  Hb  levels
>13  g/dL  in  men,  >12  g/dL  in  women).12,21,49 Otherwise,
nemia  may  recur  relatively  fast,  as  observed  in  patients
ith  Crohn’s  disease  and  ulcerative  colitis.64
Authors’  conclusion:  When  treating  IDA  with  iron
upplementation  in  GIB,  the  primary  aim  is  to  achieve
ormal  Hb  values,  and  the  additional  aim  should  be  to
ormalize  iron  status  (as  reﬂected  by  ferritin  or  TSAT
evels).
isconception  3c:  Intravenous  iron  administration
hould be  reserved  for  gastrointestinal  bleeding
atients with  very  severe  anemia  (e.g.  hemoglobin
8 g/dL)
n  the  past,  i.v.  iron  was  reserved  for  very  severe  ane-
ia  because  of  putative  side  effects  of  early  developed,
igh  molecular  weight  iron  dextrans  that  were  associated
ith  risks  of  allergic  reactions.65 Even  nowadays,  anemia
eems  to  be  left  ignored  or  treated  only  in  severe  cases.31
ecause  newer  i.v.  iron  preparations  are  generally  well  tol-
rated  when  used  according  to  their  label,12,66 patients
ith  chronic  GIB  who  are  intolerant  or  not  responding  to
ral  iron  should  receive  i.v.  iron  for  the  correction  of  IDA
nd  repletion  of  body  iron  stores.12 As  a  simple  heuristic,
.v.  iron  might  be  indicated  in  all  cases  when  Hb  levels
re  <10  g/dL  and  in  cases  when  Hb  levels  are  >10  g/dL
ogether  with  relevant  cardiac  or  respiratory  comorbidi-
ies.  Observational  studies  in  oncology  patients  have  shown
hat  i.v.  iron  treatment  can  consistently  improve  Hb  lev-
t
1
dls  across  different  baseline  Hb  categories  (Hb  <10  g/dL,
0--11  g/dL).67,68
In  clinical  practice,  GIB  is  often  associated  with  chronic
idney  disease  (CKD)69--71 a  disease  area  with  a  long  history
nd  vast  experience  in  the  effective  and  safe  use  of  i.v.  iron
or  the  treatment  of  ID  and  IDA  (with  i.v.  iron  given  alone
r  in  combination  with  an  erythropoiesis-stimulating  agent
ESA]).72 Because  iron  is  an  essential  element  required  for
 wide  range  of  cellular  and  physiological  functions,73 rapid
esolution  of  ID  with  appropriate  iron  treatment  should  be
onsidered  even  in  the  absence  of  anemia.21 In  patients  with
hronic  heart  failure,  treatment  of  ID  with  i.v.  iron  improved
unctional  outcomes  and  QoL  in  both  patients  with  and  with-
ut  anemia.52,53
Authors’  conclusion:  Intravenous  iron  administration
hould  not  be  reserved  only  for  GIB  patients  with  very
evere  anemia.
isconception  3d:  When  treating  iron  deﬁciency
nemia with  i.v.  iron  administration,  a  dose  of  500
r up  to  1000  mg  is  enough
n  fact,  in  most  studies  on  anemia  treatment  with  new
.v.  iron  preparations,  iron  was  administered  in  individ-
al  doses  of  500--1000  mg.40,74,75 However,  in  patients  with
cute  or  chronic  bleeding,  iron  deﬁcits  can  easily  exceed
000  mg  as  calculated  by  the  Ganzoni  formula,76 which
ather  underestimates  the  iron  needs.40,74,75 A  novel  and
impler  dosing  guide  for  total  dose  estimates  based  on
b  and  body  weight  (Table  2)  given  in  single  doses  of
00--1000  mg  iron  has  been  tested  in  patients  with  IBD40
nd  adopted  in  the  labels  of  i.v.  iron  preparations.77 Option
or  high  iron  doses  for  rapid  and  efﬁcient  iron  replenish-
ent  are  ferric  carboxymaltose  and,  although  data  are
carce,  low-molecular-weight  iron  dextran.  Several  clini-
al  trial  and  observational  data  that  evaluated  efﬁcacy
nd  safety  of  high-dose  iron  administration  used  these
ompounds.40,78,79
Authors’  conclusion:  Total  doses  of  i.v.  iron  administra-
ion  should  be  individualized  but  frequently  are  higher  than
000  mg;  most  available  clinical  data  are  based  on  single
oses  of  up  to  1000  mg  iron.
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hAnemia:  Misconceptions  in  gastrointestinal  bleeding  
Misconception  3e:  The  correction  of  iron
deﬁciency anemia  after  i.v.  iron  administration  is
practically  immediate
Although  the  elevation  of  Hb  levels  after  i.v.  iron  treatment
occurs  generally  faster  than  with  oral  iron,12,80 the  utiliza-
tion  of  administered  iron  and  the  process  of  erythropoiesis
need  some  time.  Therefore,  Hb  levels  do  not  increase  or
normalize  immediately  after  treatment  as  it  would  be  the
case  after  RBC  transfusion.  The  administered  iron  carbohy-
drate  complexes  are  taken  up  and  degraded  by  the  cells
of  the  reticuloendothelial  system,  followed  by  utilization
of  iron  for  repletion  of  iron  stores  or  erythropoiesis  in  the
bone  marrow.81 Analytical  control  (e.g.  assessment  of  Hb
and  iron  status  parameters)  should  be  performed  at  least  10
days  after  administering  i.v.  iron  (in  most  cases  after  hospital
discharge).
Up  to  2  months  after  i.v.  iron  administration,  elevated
ferritin  values  may  be  observed  as  a  normal  transitory
response  without  indicating  iron  overload.82,83 Additional
iron  parameters  that  should  be  checked  to  evaluate  the
erythropoietic  response  to  i.v.  iron  are  TSAT,  hemoglobin
content  of  reticulocytes  (should  increase  quickly  after  iron
treatment)  or  the  percentage  of  hypochromic  cells  (slow
decrease  after  iron  treatment).14,46
Authors’  conclusion:  The  correction  of  IDA  after  i.v.  iron
administration  is  rapid  but  takes  some  time  (several  weeks).
Misconception  3f:  The  efﬁcacy  of  i.v.  iron  for  the
treatment of  iron  deﬁciency  anemia  in
gastrointestinal  bleeding,  in  contrast  with
non-gastrointestinal  bleeding  patients,  has  not
been demonstrated
Published  clinical  evidence  on  the  use  of  i.v.  and  other  iron
treatment  in  patients  with  either  acute  or  chronic  GIB  and
IDA  is  scarce  compared  with  that  in  IBD.  However,  data  from
a  published  trial  in  patients  with  non-variceal  AUGIB79 and
recent  congress  presentations56,57,84--86 suggest  its  clinical
beneﬁt.  The  published  trial  was  designed  as  a  double-blind,
3-arm  study  (1  ×  1000  mg  i.v.  ferric  carboxymaltose;  100  mg
BID  oral  ferrous  sulfate  for  12  weeks;  placebo).79 From  as
early  as  week  4  onwards,  median  Hb  levels  were  signiﬁcantly
higher  among  iron-  vs  placebo-treated  patients.  Unfortu-
nately,  most  patients  in  this  study  were  not  iron  deﬁcient
at  baseline,  and  no  signiﬁcant  differences  in  Hb  outcome
between  the  two  iron  groups  have  been  detected.  However,
from  week  1  onwards,  ferritin  levels  in  the  i.v.  iron  group
were  higher  than  those  in  the  oral  iron  and  the  placebo
group.  Furthermore,  ferritin  levels  of  oral  iron-treated
patients  decreased  by  50%  from  baseline  to  week  4.  This
is  an  important  aspect,  because  a  study  in  patients  with  IBD
revealed  that  patients  with  low  ferritin  levels  (<100  g/L)
at  the  end  of  treatment  experienced  earlier  recurrence  and
reinitiation  of  iron  therapy.64 Anticipated  results  from  an
ongoing  trial  (ClinicalTrials.gov  NCT01690585)  investigating
i.v.  ferric  carboxymaltose  in  patients  with  GIB  will  add  evi-
dence  to  this  area.
I
t
b69
Recently  presented  data  suggest  effectiveness  of  fer-
ic  carboxymaltose  in  improving  Hb  levels  in  patients  after
cute  GIB,85,86 angiodysplasia57 and  outpatients  with  GIB
ue  to  different  conditions  referred  from  a gastroenter-
logy  department  for  anemia  treatment.84 In  patients  after
cute  GIB,  a  randomized  comparison  vs  oral  iron  showed
aster  Hb  response  and  normalization  of  TSAT  by  Day  7
ost  treatment  with  ferric  carboxymaltose,85 and  in  another
tudy  signiﬁcant  Hb  increase  in  patients  >75  years  of  age,
harlson  index  >3  or  hospital  admission  Hb  <10  g/dL  was
eported.86
Clearly,  the  lack  of  published  evidence  affects  clini-
al  practice.  A  retrospective  study  in  Denmark1 showed
hat  only  a minority  of  patients  (16%)  hospitalized  for  non-
ariceal  AUGIB  received  a  recommendation  to  begin  oral  iron
upplementation.  Intravenous  iron  was  not  even  considered
nd  more  than  80%  of  admitted  patients  were  anemic  at  the
ime  of  discharge.
The  lack  of  guidance  on  the  management  of  GIB-related
DA  is  illustrated  by  the  fact  that  among  29  guidelines
rom  different  professional  associations,  only  three  refer
o  gastrointestinal  diseases;  two  of  them  referring  to  IBD-
ssociated  IDA21,49 and  only  one  to  digestive  diseases  in
eneral.12 In  lieu  of  clinical  data  and  guidelines  in  patients
ith  GIB,  there  is  published  evidence  of  effective  blood/iron
anagement  and  i.v.  iron  treatment  in  patients  bleeding
rom  another  source  (e.g.  colon  cancer87,88 or  surgery89).
uch  results  can  be  reasonably  extrapolated  to  anemic
atients  with  GIB.
Authors’  conclusion:  The  effectiveness  of  i.v.  iron  for  the
reatment  of  IDA  in  patients  with  GIB  is  demonstrated.
isconception  3g:  Intravenous  iron  treatment  is
nsafe
he  persistent  misconception  about  safety  of  i.v.  iron  is
ainly  based  on  historical  reports  of  anaphylactic  reac-
ions  and  high  serious  adverse  event  rates  associated  with
igh-molecular  weight  iron  dextrans65 (no  longer  mar-
eted  in  many  regions),  and  a  superparamagnetic  iron
xide  preparation90 (marketing  authorization  withdrawn  in
urope  at  the  manufacturer’s  request).91 With  other  prepa-
ations,  the  incidence  of  serious  adverse  events  is  very
are  and  hypersensitivity  usually  self-limited.61,92--94 Fur-
hermore,  the  European  Medicines  Agency  reviewed  the
eneﬁt-risk  balance  of  i.v.  iron-containing  medicinal  prod-
cts,  concluding  that  the  beneﬁts  of  i.v.  iron  continue  to
utweigh  the  risks  in  the  treatment  of  ID  when  the  oral  route
s  insufﬁcient  or  poorly  tolerated.66
Authors’  conclusion:  Intravenous  iron  treatment  is  safe.
isconception  3h:  Red  blood  cell  transfusion  is
ndicated in  hemodynamically  stable  patients  when
emoglobin  levels  drop  below  8--9  g/dLn  general,  it  is  not  recommended  to  simply  transfuse  to  a
hreshold  Hb  level;  clinicians  need  to  consider  age,  comor-
idities,  cause  and  severity  of  bleeding,  etc.  in  any  case.
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f  RBC  transfusion  is  deemed  necessary,  a  restrictive  pol-
cy  should  be  considered,  unless  ischemic  heart  disease  is  a
omorbidity.95,96 Results  of  the  TRIGGER  trial95 suggest  that
he  Hb  threshold  for  transfusion  can  be  safely  lowered  (Hb
8.0  g/dL)  without  adversely  affecting  clinical  outcomes  in
atients  with  acute  upper  GIB.  In  another  study,  restricted
ransfusions  (Hb  <7.0  g/dL)  in  patients  with  acute  upper  GIB
ere  associated  with  lower  mortality.97
Although,  a  restrictive  transfusion  policy  means  that
any  patients  will  remain  anemic  for  some  time,  it  does
ot  mean  ignoring  IDA  and  doing  nothing.  In  contrast,
t  provides  time  to  manage  IDA  with  available  transfu-
ion  alternatives,  mainly  i.v.  iron.  A  retrospective  study
f  patients  with  moderate  (Hb  <10  g/dL)  to  severe  (Hb
8.0  g/dL)  IDA  who  required  chronic  transfusion  support
>2  RBC  transfusions  within  one  year)  in  ﬁve  Italian
ransfusion  centers  showed  the  effectiveness  of  i.v.  iron
reatment  in  the  reduction  of  RBC  requirements.98 Treat-
ent  with  ferric  carboxymaltose  was  associated  with  a
igniﬁcant  reduction  of  the  median  annual  number  of
ransfused  RBC  units  from  6  (interquartile  range  4--15)
o  0  (0--5)  and  median  Hb  levels  nevertheless  increased
igniﬁcantly  from  8.7  g/dL  (8.1--9.2  g/dL)  to  11.0  g/dL
9.9--11.7  g/dL).
A  restrictive  transfusion  policy  is  in  line  with  the  guideline
or  the  management  of  IDA  in  digestive  diseases,  recom-
ending  to  reserve  blood  transfusions  for  patients  who  have
ymptomatic  IDA  despite  treatment  with  iron  or  for  patients
ho  are  at  risk  of  cardiovascular  instability  due  to  the
egree  of  their  anemia.12 Such  a  policy  is  also  backed  by  the
Choosing  Wisely’  initiative  of  the  American  Board  of  Inter-
al  Medicine  (ABIM)  and  the  American  Association  of  Blood
anks,  asking  to  limit  the  administration  of  RBC  units  to  the
bsolutely  necessary  minimum  and  a  restrictive  Hb  threshold
f  7.0--8.0  g/dL.99 Furthermore,  RBC  transfusions  should  not
e  used  as  treatment  for  iron  deﬁciency  in  patients  without
emodynamic  instability.
Authors’  conclusion:  Blood  transfusion  should  be
estricted  to  hemodynamically  instable  patients  and  the
bsolutely  necessary  minimum  number  of  RBC  units.  If
ransfusion  is  deemed  necessary  in  hemodynamically  sta-
le  patients  who  do  not  present  with  cardiovascular  risk
actors,  a  restrictive  Hb  threshold  of  7.0--8.0  g/dL  should
e  considered.
isconception  3i:  After  initiation  of  blood
ransfusion,  no  further  i.v.  iron  treatment  is
eeded
n  clinical  practice  and  guidelines,  RBC  transfusions  are
ften  mentioned  as  treatment  without  considering  or
ddressing  needs  for  further  iron  repletion  or  maintenance
reatment.100 However,  RBC  transfusions  raise  Hb  levels  only
ransiently  without  correcting  the  underlying  pathology  and
ron  depletion  at  the  same  time,  making  the  recurrence
f  IDA  more  likely.12,64 Accordingly,  iron  status  parameters
nd  whole  blood  counts  should  be  monitored  as  part  of
ransfusion  follow-up.48 Notably,  a  single  RBC  unit  (300  mL)
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ontains  approximately  150  mg  iron,  whereas  modern  i.v.
ron  preparations  can  be  given  at  doses  up  to  1000  mg  iron
er  administration.  With  i.v.  iron,  the  production  of  appro-
riate  red  blood  cells  (erythropoiesis)  and  the  repletion  of
ron  stores  is  facilitated.81
It  is  prudent  to  keep  in  mind  that  transfusions  are  a  transi-
ory  measure  and  not  intended  to  restore  normal  Hb  values.
nly  the  minimum  number  of  RBC  units  that  are  needed  to
each  a  safe  Hb  level  and  hemodynamic  stabilization  of  the
atient  should  be  transfused.  Restoration  of  normal  Hb  lev-
ls  (and  iron  stores)  can  be  achieved  with  following  i.v.  iron
reatment  as  recommended12,89 and  recently  presented  even
or  patients  with  acute  GIB.86
Authors’  conclusion:  Even  after  blood  transfusion,  i.v.
ron  treatment  is  needed  in  most  cases.
isconception  3j:  When  oral  iron  is  administered,
igher doses  than  usual  should  be  prescribed  in
atients with  gastrointestinal  bleeding
here  is  little  evidence  to  support  high  doses  of  oral  iron
n  patients  with  GIB,  as  iron  absorption  may  be  generally
mpaired.  Controlled  efﬁcacy  studies  of  oral  iron-based  IDA
reatment  in  adult,  elderly,  pediatric  and  pregnant  popula-
ions  support  low-dose  oral  iron  supplementation  either  in
ablet  or  liquid  form.101--104 In  the  absence  of  inﬂammation
r  chronic  disease,  the  upper  limit  of  daily  iron  absorption
s  approximately  10  mg  iron/day  (under  inﬂammatory  condi-
ions  even  less).102,105 Thus,  a  dose  of  100  mg  elemental  iron
aily  is  sufﬁcient  and  higher  doses  will  only  increase  the  risk
f  adverse  gastrointestinal  effects  (e.g.  nausea,  vomiting,
onstipation  and  diarrhea).
In  general,  the  response  to  oral  iron  (rate  with  normalized
b  levels)  strongly  depends  on  factors  such  as  comorbidities,
ge  and  gender  that  often  inﬂuence  levels  of  inﬂammatory
ytokines  and  thereby  affect  intestinal  iron  absorption  and
tilization.50,60
Authors’  conclusion:  When  oral  iron  is  administered,
igher  doses  than  usual  should  not  be  prescribed  in  patients
ith  GIB.
isconception  3k:  The  response  of  iron  deﬁciency
nemia to  oral  iron  supplementation  is  almost
nvariably excellent  in gastrointestinal  bleeding
part  from  gastrointestinal  side  effects  and  the  risk  of
asking  a new  bleeding  period  due  to  stool  coloring,  main
imitations  of  oral  iron  supplementation  are  slow  response
nd  poor  tolerance/compliance  (see  Section  3j).102,105 In
on-variceal  AUGIB,  a  single  1000  mg  i.v.  iron  dose  achieved
quivalent  Hb  outcomes  over  three  months  as  the  twice
aily  oral  intake  of  100  mg  of  iron  (approx.  36  g total  iron
ose).79 A  recently  presented  randomized,  controlled  study
n  patients  with  IDA  after  acute  GIB  showed  signiﬁcantly
etter  Hb  normalization,  Hb  response  (≥2  g/dL)  and  TSAT
ncrease  in  ferric  carboxymaltose-compared  to  oral  iron-
reated  patients.85 In  chronic  GIB,  absorption  of  oral  iron
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(Anemia:  Misconceptions  in  gastrointestinal  bleeding  
may  be  severely  compromised  and  persistent  blood  loss  will
exceed  the  capacity  of  intestinal  absorption  of  iron.106
Furthermore,  patient  adherence  to  long-term  oral  treat-
ments  is  a  general  issue107,108 and  particularly  with  oral  iron
due  to  its  known  gastrointestinal  side  effects  such  as  consti-
pation,  nausea  and  diarrhea.109 In  patients  after  acute  GIB,
abdominal  pain  and  constipation  were  reported  by  6.7%  and
21%  of  oral  iron-treated  patients  whereas  no  side  effects
were  reported  for  the  i.v.  iron  group.  In  line,  treatment
adherence  was  lower  with  oral  vs  i.v.  iron  (87%  vs  100%).85
In  daily  life,  patient  adherence  may  be  even  lower  than
in  the  controlled  environment  of  clinical  trials  and  further
limit  the  effectiveness  of  oral  iron  treatment.  While  oral
iron  (fumarate)  is  associated  with  increased  clinical  disease
activity  in  IBD  patients,110 studies  on  the  risk  of  rebleeding
in  patients  with  GIB  taking  oral  iron  are  lacking.  Notably,
even  if  Hb  levels  improve  with  oral  iron,  repletion  of  iron
stores  (ferritin  levels)  will  hardly  be  achieved  within  a  rea-
sonable  time  period  due  to  the  poor  iron  absorption  and
generally  large  iron  deﬁcits,  thus,  increasing  the  risk  of
IDA  recurrence.64,89 Considering  that  many  GIB  patients  may
have  chronic  comorbidities  with  an  underlying  inﬂammatory
status,  oral  iron  is  not  recommended.48 Despite  these  valid
precautions,  there  may  be  cases  where  oral  iron  treatment
may  be  sufﬁcient  if  well  tolerated.
Authors’  conclusion:  The  response  of  IDA  to  the  oral  iron
supplementation  is  variable  and  depends  on  factors  such  as
age,  gender,  concomitant  medications  and  comorbidity.
Misconception  3l:  Treatment  with  i.v.  iron  has  no
role in patients  with  gastrointestinal  bleeding  seen
in the  emergency  room  for  self-limiting  bleeding
who are  discharged  early,  without  being  admitted
to hospital
Diagnosis  and  early  intervention  in  the  emergency  room  may
be  crucial  in  patients  with  sub-acute  but  self-limiting  GIB
and  IDA,  even  though  iron  status  analysis  may  not  be  avail-
able  on  a  24-h  basis  in  all  emergency  departments.  The  need
for  blood  conservation,  particularly  in  patients  not  requiring
acute  transfusion,  and  proper  resource  and  cost  manage-
ment  in  the  emergency  room  suggest  a  role  for  i.v.  iron  in  the
management  of  acute  as  well  as  chronic  GIB.55,111--113 While
many  emergency  cases  of  self-limiting  bleeding  stop  sponta-
neously,  at  least  patient’s  iron  status  and  risk  of  developing
ID  or  IDA  should  be  followed  up  by  referring  to  a  primary
care  physician  after  discharge.  In  a  Spanish  Day  Hospital,
34.7%  of  patients  treated  with  i.v.  iron  treatment  after  GIB
where  referred  from  an  emergency  department.56
In  a  recently  presented  fast-track  anemia  management
program  within  an  emergency  department  that  emphasized
early  intervention  with  i.v.  iron  (No.  =  202  patients  with
moderate-to-severe  anemia  [Hb  <11.0  g/dL]),  44%  of  the
referred  cases  related  to  chronic  GIB.112 The  use  of  i.v.  fer-
ric  carboxymaltose  was  associated  with  a  3.9  g/dL  mean
increase  in  Hb  after  4  weeks  and  an  84%  response  rate.
In  addition,  a  low  transfusion  rate  (17%)  was  achieved,
demonstrating  that  i.v.  iron  use  in  emergency  departments  is
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ossible,  beneﬁcial  and  safe.112 Although  further  data  and
onger  follow-up  are  needed,  clearly  i.v.  iron  does  have  a
ole  for  patients  with  sub-acute,  self-limiting  GIB  and  IDA,
ith  close  follow-up  needed  to  prevent  relapse  or  transfu-
ion.
Moreover,  patients  in  the  emergency  room  may  have  ID
ndependent  of  whether  they  have  any  GIB  because  anemia
s  highly  prevalent  even  in  developed  countries.114,115 This
osters  the  need  for  follow-up  if  not  an  early  intervention.
Authors’  conclusion:  Treatment  with  i.v.  iron  may  be
rucial  in  patients  with  IDA  seen  in  the  emergency  room
or  self-limiting  bleeding  who  are  discharged  early,  without
ven  being  admitted  to  hospital.
ther
isconception  4a:  The  role  of  the
astroenterologist  ends  when  the  gastrointestinal
leeding  event  is  controlled  (stopping
astrointestinal  bleeding  is  the  priority,  anemia  is
ot relevant)
n  parallel  with  the  immediate  needs  of  managing  and  treat-
ng  the  source  of  GIB,  speciﬁc  treatment  goals  and  proper
urveillance  of  patients  are  needed  to  correct  IDA  or  ID  in
 timely  manner.  Considering  that  QoL  declines  very  fast  in
nemic  patients  with  GIB  while  it  remains  stable  in  non-
nemic  patients,34 the  gastroenterologist  should  consider
nemia  as  a  serious  comorbid  condition  and  treat  it  with
he  same  rigor  as  the  bleeding.  Control  or  resolution  of  GIB
nd  anemia  do  not  exclude  each  other.  While  treatment  of
he  underlying  disease  is  intended  to  contain  or  prevent  fur-
her  loss  of  blood,  parallel  iron  replacement  treatment  is
ntended  to  resolve  anemia  and  replenish  iron  stores.12 If
atients  are  not  followed-up  at  the  gastroenterology  depart-
ent,  referring  physicians  should  be  instructed  to  continue
nemia  and  iron  status  monitoring  as  indicated  by  the  rele-
ant  guidelines12 and  initiate  treatment  as  needed.
Authors’  conclusion:  The  role  of  the  gastroenterologist
s  not  only  to  control  the  GIB  event  but  also  to  treat  IDA
nd  ID.
isconception  4b:  Intravenous  iron  formulations
re expensive  and  not  cost-effective
hile  oral  iron  may  appear  inexpensive  and  convenient,  it
s  associated  with  a  slow  Hb  response  and  gastrointestinal
dverse  events  that  can  increase  indirect  costs.  A  cost-
inimization  analysis  of  treating  IDA  in  patients  with  colon
ancer  before  surgery  showed  lower  costs  with  a  high-dose
.v.  iron  (ferric  carboxymaltose)  compared  with  oral  iron
1827  vs  2101  D  /patient),  mainly  based  on  higher  efﬁcacy
Hb  increase  in  a  short  period  of  time)  that  is  reﬂected
116n  shorter  hospital  stays  and  less  transfusion  needs.
onversely,  higher  costs  were  observed  with  an  i.v.  iron
hat  requires  more  frequent  administrations  (iron  sucrose;
312  D  /patient);  maybe  because  the  dose  of  iron  sucrose
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bleeding and outcomes in patients hospitalized with upper gas-2  
as  calculated  using  the  Ganzoni  formula  that  seems  to
nderestimate  iron  needs.
Another  cost-effectiveness  analysis  in  a  fast-track  ane-
ia  clinic  for  the  management  of  moderate-to-severe  IDA
omparing  an  i.v.  iron-based  fast-track  protocol  with  the
revious  transfusion-based  standard  care  showed  cost  sav-
ngs  of  78  D  /patient  with  ferric  carboxymaltose  vs  RBC
ransfusions  (594  vs  672  D  /patient).113
Authors’  conclusion:  Intravenous  iron  can  be  cost-
ffective.
onclusions
astroenterologists  have  a  unique  position  in  the  follow-up
nd  care  of  referred  patients  with  GIB,  particularly  with
he  objective  of  identifying  and  improving  the  underlying
ause(s).  Current  practice  is  not  standardized  and  is  subop-
imal.  First,  more  research  and  greater  awareness  of  the
hallenges  of  ID  and  IDA  in  the  GIB  setting  are  needed,
iming  to  inﬂuence  the  clinical  outcomes  and  QoL  of  these
atients  and  minimize  the  need  for  blood  transfusions.  Sec-
nd,  all  clinicians  involved  in  patient  care  should  engage  in
ddressing  misconceptions  to  achieve  a  positive  impact  on
oL  and  minimize  the  risk  of  persistent  blood  loss,  inad-
quate  iron  status  at  hospital  discharge  and  early  anemia
ecurrence.  Commitments  from  the  health  care  network
o  better  coordination  with  evidence-based  guidelines  that
eneﬁt  patients  with  ID/IDA  would  be  ideal.
While  there  are  few  controlled  studies  evaluating  the
fﬁcacy  of  IDA  treatment  in  GIB,  consistent  data  exist
howing  that  patients  with  GIB  can  beneﬁt  from  diligent
nvestigation  and  treatment  of  IDA,  and  allowing  for  some
undamental  statements  (Table  1)  in  response  to  com-
on  misconceptions.  Oral  iron  is  an  acceptable  ‘ﬁrst-line’
ption  primarily  for  clinically  stable  patients  with  only
ild  anemia  and  without  risk  of  rebleeding,  gastrointestinal
omplications  or  sequelae,  chronic  inﬂammation,  malab-
orption  or  tolerability  issues.  When  using  i.v.  iron,  a  faster
mprovement  in  Hb  and  iron  status  can  be  expected.  While
ost  patients  with  acute  GIB  experience  signiﬁcant  blood
oss  prior  to  endoscopic  interventions,  transfusions  should
lways  be  restricted  to  rescue  treatments  and  combined
ith  i.v.  iron  supplementation  to  replete  iron  stores.  The
b  threshold  for  transfusion  should  be  kept  low  if  there  are
o  cardiovascular  comorbidities  present.
In  light  of  the  available  treatment  options,  the  ‘status
uo’  of  ignoring  ID  and  IDA  in  the  GIB  does  not  seem  appropri-
te.  The  treatment  goal  should  not  only  be  to  stop  bleeding
ut  to  completely  correct  ID/IDA  in  a  deliberate,  efﬁcient
nd  fast  manner  and  minimize  the  risk  of  anemia  recurrence.
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